Cytovance Biologics, an Oklahoma City, Oklahoma-based biologics contract manufacturer, was inspected by the US Food and Drug Administration over an eight-day period in July 2017. The inspection focused on the company’s quality systems.

The company reported that overall the inspection was positive, and the inspector acknowledged that the site had already identified and taken action on most of four observations cited in the inspection. Specifically, Cytovance had taken action to address facility improvements. All the facility updates are scheduled to be completed during Cytovance’s end-of -summer shutdown.

Source: Cytovance Biologics